Vatiquinone

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Inherited Mitochondrial Disease

Conditions

Inherited Mitochondrial Disease

Trial Timeline

Jun 22, 2022 → Apr 15, 2025

NCT ID

NCT05218655

About Vatiquinone

Vatiquinone is a phase 3 stage product being developed by PTC Therapeutics for Inherited Mitochondrial Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05218655. Target conditions include Inherited Mitochondrial Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07159139	Pre-clinical	Active	—	—	Mitochondrial Disease
NCT05515536	Phase 3	Active	Dec 8, 2022	Dec 31, 2027	Friedreich Ataxia
NCT05485987	Phase 2	Completed	Oct 12, 2022	Aug 29, 2024	Friedreich Ataxia
NCT05218655	Phase 3	Completed	Jun 22, 2022	Apr 15, 2025	Inherited Mitochondrial Disease
NCT04378075	Phase 2/3	Terminated	Sep 28, 2020	Dec 27, 2023	Mitochondrial Diseases

Competing Products

4 competing products in Inherited Mitochondrial Disease

See all competitors

Product	Company	Stage	Hype Score
Umbilical cord blood transplantation with HSC835	Novartis	Phase 1/2	24
Cysteamine Bitartrate	Amgen	Phase 2	35
PF-05089771 + Placebo	Pfizer	Phase 2	35
BIIB074 + Placebo	Biogen	Phase 2	32